No Prescription |
 |
 | ||
|
Cilicaine VK Beepen VK |
|
| ||
No Prescription » Prescription Drugs 4 » Cilicaine VK Beepen VK IndicationsWhen oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms. Therapy should be guided by bacteriological studies including sensitivity tests and by clinical response.For prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or Sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation.Note: Oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery lower intestinal tract surgery sigmoidoscopy or complications of childbirth.Dosage and Administration:250mg to 500mg every four to six hours preferably one hour before food. The dosage should be determined according to sensitivity of the organisms and severity of the infection.Prevention of recurrence following rheumatic fever: 250mg twice a day continuously. Buy Cilicaine VK Beepen VK and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About Cilicaine VK Beepen VK: Product Type: Prescription Drugs 4 Cilicaine VK ( Beepen VK Ledercillin VK Pen-Vee K V-Cillin K Veetids Generic Penicillin VK ) Cilicaine VK (Beepen VK Ledercillin VK Pen-Vee K V-Cillin K Veetids Generic Penicillin VK) Beepen VK Ledercillin VK Pen-Vee K V-Cillin K Veetids Generic Penicillin VK 250mg 50 500mg 50 250mg 50 Capsules 250mg 100(2 x 50) Capsules 500mg 100(2 x 50) Capsules 500mg 50 Capsules Beepen VK Ledercillin VK Pen-Vee K V-Cillin K Veetids Generic Penicillin VK Cilicaine VK
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
